Abstract: In DN-DISC1 mice, a mouse model for major mental illnesses, the model that expresses pathological phenotypes relevant to schizophrenia, mood disorders, and addiction simultaneously, the inventors of the present invention found pronounced levels of oxidative stress in the prefrontal cortex, but not in the striatum. These mice also displayed greater amounts of GAPDH-Siah1 binding, a protein-protein interaction that is activated under exposure to oxidative stress. The present inventors investigated the role of oxidative stress in other organ systems. As detailed herein, the inventors found that GAPDH-Siah1 binding was increased in mouse models of cardiac failure. It was also found, that certain novel analogs of deprenyl, significantly inhibited GAPDH-Siah1 binding in cardiac tissue.

Abstract: An irinotecan hydrochloride composite phospholipid composition, preparation method and uses thereof in the preparation of drugs for treating tumors or drug resistant tumors. The composite phospholipid composition comprises irinotecan hydrochloride, composite phospholipid, cholesterol, long-circulating membrane material, surfactant and a buffer medium. The composition improves stability of lipid formulation and the anti-tumor effect of irinotecan hydrochloride, and can overcome multidrug resistance of a tumor.

Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.

Abstract: The present invention provides pharmaceutical methods and formulations for treating collapsing trachea and related disorders.

Abstract: The invention relates to a method of treatment using a solid oral pharmaceutical dosage form comprising an opioid receptor antagonist for use in the treatment of opioid induced constipation comprising the opioid antagonist equivalent to 24 mg of naloxone hydrochloride as twice daily formulation or equivalent to 48 mg of naloxone hydrochloride as once daily formulation, characterized in that the opioid antagonist has a rapid first pass metabolism with a plasma half-life of 2 hours or less in humans within the first 3 hours of oral administration of a solution, wherein the steady state pharmacokinetics result in a constant level of naloxone in the bloodstream, wherein the pharmacokinetics are independent of whether the dosage is administered once or twice daily, wherein the oral dosage form releases the opioid antagonist in a prolonged manner, wherein the in vitro release rate of the opioid antagonist measured using the paddle stirrer method according to Ph. Eur. at 75 rpm in 1000 ml 0.

Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.

Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.

Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.

Abstract: A spray dried-powder composition for inhalation comprising particles (X) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the United States Pharmacopoeia at 50 rotation per minute, 37° C. in 900 milliliters of an aqueous dissolution medium adjusted at pH 1.2 and containing 0.3% of sodium laurylsulfate.

Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.

Abstract: Provided is Compound (I) or a pharmaceutically acceptable salt thereof, which is an inhibitor of TrkA kinase and is useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation and inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, diseases related to an imbalance of the regulation of bone remodeling, and diseases resulting from Connective Tissue Growth Factor aberrant signaling.

Abstract: Compositions and methods are described herein for treating a bone disorder, including a bone-targeting complex including an inhibitor of nitric oxide synthase uncoupling; a bone-targeting agent; and a linker coupling the inhibitor of nitric oxide synthase uncoupling to the bone-targeting agent.

Abstract: The present application relates to Janus kinase (JAK) inhibitors, including 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, for the treatment of a dry eye disorder or ameliorating a particular symptom of a dry eye disorder, such as eye discomfort, visual disturbance, tear film instability, tear hyperosmolarity, and inflammation of the ocular surface, as well as kits and compositions, including topical compositions, related thereto.

Abstract: In certain embodiments the present invention involves methods of killing tumor cells that comprise an oncogenic PDGFR mutation, and methods of treating subjects having tumors that comprise such tumor cells. In some embodiments such methods involve using PI3K inhibitors, or a combination of a PI3K inhibitor and an mTOR inhibitor, or a dual PI3K/mTOR inhibitor. The present invention also provides methods for determining whether a subject is a candidate for treatment, methods for evaluating the efficacy of treatment, and other methods, compositions, model systems, and assays.

Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

Abstract: The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate maternal nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation. Embodiments of the present invention relate to the Vitamin B2 for use in the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in the offspring, wherein the vitamin B2 is administered to women desiring to get pregnant and/or to the mother during pregnancy and/or lactation and to maternal food compositions that can be used for this purpose.

Abstract: Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosed methods include administering to an individual in need of such treatment a composition that may include an IRAK1/4 inhibitor. In other aspects, the method may include administration of a BLC2 inhibitor.

Abstract: Provided herein are multiple solid forms of a defined ?,{acute over (?)}-disubstituted dihydroxy cyclopentyl compound, and methods for the preparation and use thereof. In one aspect, there are provided crystalline forms of said cyclopentyl compound, and methods for the preparation and use thereof. In another aspect, there are provided substantially amorphous forms of said dihydroxy cyclopentyl compound, and methods for the preparation and use thereof. In yet another aspect, there are provided compositions containing compounds according to the present invention. In certain aspects, such compositions are suitable for delivery of active agents according to the present invention to a subject in need thereof. In another aspect of the invention, there are provided methods for the treatment of a variety of indications, including glaucoma, ocular hypertension, and the like.

Abstract: A pharmaceutical composition for enhancing male erectile function comprising an erectile function-enhancing amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatmedin-C) and analogue LR3 IGF1 in admixture with a pharmaceutically-acceptable diluents or carrier. Such compositions optionally further comprise compounds selected from an androgen, particularly, testosterone and dihydrotestosterone, a vasodilator, PDE5 inhibitor and prostaglandin E1.

Abstract: The present invention relates to methods and kits for reducing the occurrence of preterm delivery and other pregnancy-related conditions in pregnant female subjects exhibiting one or more risk factors for preterm delivery and other pregnancy-related conditions. For example, the present invention relates to methods for reducing the occurrence of preterm delivery in a pregnant female subject having no history of preterm delivery and exhibiting one or more risk factors for preterm delivery (e.g., smoking during pregnancy). The methods and kits provide for the administration of a steroid hormone to the pregnant female subject.

Abstract: The present invention relates to methods and compositions for treating and/or preventing allergic diseases and/or conditions, as well as for preventing acute allergic responses by administering a therapeutically effective amount of 1,25-dihydroxy vitamin D3 (1,25D3).

Abstract: Aspirin is chemically modified to generate a prodrug that releases aspirin in cellular milieu. The prodrug has a lipophilic tail that may enhance uptake efficiency in nanoparticles. Nanoparticles including the prodrugs may be effective for treating inflammatory disorders, including neurodegenerative disorders.

Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.

Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.

Abstract: The present invention provides a method of inhibiting renal fibrosis in a subject in need thereof.

Abstract: This invention is about the compositions and methods for assessing and treating vascular endothelial dysfunction. Various aspects provide a method for treatment of vascular endothelial dysfunction, comprising administering a composition comprising nicotinamide mononucleotide and a pharmaceutical excipient to a subject. In one embodiment the dose is administered to subjects in response to the indicator. In another embodiment the dose is administered chronically to subjects.

Abstract: Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.

Abstract: Disclosed is a Glechoma longituba (Nakai) Kupr. extract, specifically compounds I and II, a preparation method for same, and a use thereof in preparing a medicament for blood glucose decease, blood lipids decrease, weight loss, and kidney disease treatment or a method for treatment of said diseases, and a composition containing the extract.

Abstract: A composition, including a fixed dose composition, comprising Compound (I), Compound (II), and Compound (III) for the treatment of hepatitis C, and methods of manufacture thereof.

Abstract: Compositions and methods are described herein for treating a bone disorder, including a bone-targeting complex including an activator of nitric oxide synthase; a bone-targeting agent; and a linker coupling the activator of nitric oxide synthase to the bone-targeting agent.

Abstract: Combination powdered material, including a first powder composition and a second powder composition, the first powder composition including cellulose particulate material and the second powder composition including starch particles, alone or in combination with talc particles.

Abstract: The present invention provides methods for alleviating pain and discomfort associated with a dry eye condition; methods for alleviating pain and discomfort while minimizing at least one skin imperfection; and methods for alleviating pain and discomfort while facilitating wound healing. The methods involve administering to a subject in need thereof a composition comprising hyaluronan with high elasticity.

Abstract: Described herein are methods and compositions for increasing dermal concentrations of glycosaminoglycans (GAG), including hyaluronic acid. Exemplary methods involve a one-step protocol and a three-step protocol. Either method can be used over a 90-day treatment period.

Abstract: Described herein are compositions and methods for the increasing the quantity of lipids secreted from meibomian glands. Such compositions and methods are useful for the treatment of meibomian gland dysfunction and disorders resulting therefrom.

Abstract: The present invention relates to sulfur compositions which are useful, for example, for treating a NO deficiency disorder, supplementing deficits in circulating nitrite, and/or improving bodily endurance or exercise performance.

Abstract: This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject.

Abstract: The invention concerns the use of an antimicrobial composition comprising metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative for the topical treatment or prevention of skin, skin adnexa or mucosa diseases which are caused by infection with at least one microorganism. The invention also concerns a bandaging material or patch comprising an antimicrobial composition which comprises metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative. The antimicrobial composition (“AgXX”) has a broad-spectrum effect against bacteria (a: E. coli) and fungi (b: Pathogen is yeast and c: Penicillium).

Abstract: Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoparticle, such as nanoplates, silver nanoplates or silver platelet nanoparticles, and to the solutions and substrates prepared by the methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates. The process can also include increasing the concentration of silver nanoplates within the solution, and thus increasing the solution optical density.

Abstract: Materials capable of delivering stabilized free radicals to targeted treatment sites. The materials comprise semi-crystalline, hydrolytically degradable polymers that are subjected to ionizing radiation to create stabilized free radicals therein. Upon exposure to oxygen containing aqueous media, the materials generate reactive oxidative species which are useful in biological processes.

Abstract: Disclosed are methods of making a genetically modified immune cell for modifying a tumor microenvironment (TME) and methods of modifying a tumor microenvironment (TME). In some embodiments, the method can include delivering a first vector to an immune cell, wherein the first vector comprises a nucleic acid encoding a protein that induces T-cell proliferation, promotes persistence and activation of endogenous or adoptively transferred NK or T cells and/or induces production of an interleukin, an interferon, a PD-1 checkpoint binding protein, HMGB1, MyD88, a cytokine or a chemokine. Methods of modulating the suppression of the immune response in a tumor microenvironment, minimizing the proliferation of tumor and suppressive cells, and increasing the efficiency of an anti-cancer therapy, anti-infection therapy, antibacterial therapy, anti-viral therapy, or anti-tumoral therapy are also provided.

Abstract: A colostrum derived bioactive supplement derived of a number of cleaved protein fragments. The colostrum supplement is utilized with milk protien and Leucine to provide improved muscular function and exercise recovery.

Abstract: The present invention relates to a composition for treating inflammatory brain diseases, which includes stem cell-derived exosomes as an active ingredient. The stem cell-derived exosomes according to the present invention can be usefully applied to the treatment of inflammatory brain diseases, because the exosomes have outstanding therapeutic effects, including inhibiting cell death due to inflammation in nerve cells, increasing the survival rate in an inflammatory-brain-disease animal model, and substantially reducing brain damage and inflammatory cytokine levels due to inflammatory reactions such as edema.

Abstract: The invention provides cell therapy compositions and associated methods. In particular embodiments, improved therapeutic cells and improved cell-based gene therapies for promoting cell or tissue formation, regeneration, repair or maintenance in a subject in need thereof are provided.

Abstract: The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.

Abstract: Methods of isolating distinct specific cell types within mixed populations of cells. Methods of isolating specific cell types among pancreatic cells, particularly from human islets of Langerhans. Markers and combinations thereof for use in methods of isolating insulin producing islet beta cells for treatment of diabetes.

Abstract: The present invention provides a food supplement, which comprises: a placental extract and an oil; which would promote the proliferation of CD34+ stem cells and increase the telomerase activity to achieve rejuvenation and anti-aging.

Abstract: The present technology provides for methods for generation and isolation of granulosa cells and/or granulosa cell precursors from multi-potent cells, wherein the granulosa cells and/or granulosa cell precursors are useful in methods for growth and maturation of follicles or follicle-like structures. Additionally, the present technology also provides for methods of increasing steroidal hormones in a subject in need thereof.

Abstract: An antibacterial analgesic anti-inflammatory salve comprising 62 percent by volume of beeswax; 10 percent by volume of smectite clay that was pushed through a number 200 mesh sieve having openings of 0.0029 inches; and 28 percent by volume of a plurality of antibacterial, antifungal, analgesic and anti-inflammatory organic oils derived from vegetable matter. A method for making an antibacterial analgesic anti-inflammatory salve.

Abstract: A composition for wound healing and/or skin treatment comprises honey and a carbonate and/or bicarbonate salt. The salt is preferably capable of releasing CO2. The composition may optionally comprise thickeners and/or organic acids. Wound dressings, kits and treatment methods are also provided.